Oasmia Pharmaceutical Priced, Nasdaq: OASM

Developing formulations of widely-used cancer drugs for humans and dogs.

Industry: Health Care

Latest Trade: $1.02 0.00 (0.0%)

First Day Return: -3.9%

Return from IPO: -74.9%

Industry: Health Care

We are a pharmaceutical company focused on innovative treatments within human and animal oncology. Our product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. We believe our formulation may result in improved safety, efficacy and ease of administration over existing drugs. Our initial development and commercialization efforts are focused on creating novel formulations of well-established chemotherapeutic drugs that can be used for the treatment of cancer in both humans and companion animals. We have four human oncology product candidates in pre-clinical and/or clinical development, and two veterinary oncology product candidates. We disclosed top-line Phase III data for our lead human oncology product candidate in the fourth quarter of 2014. In February 2014, we received conditional approval by the United States Food and Drug Administration for our initial veterinary oncology product.
more less
IPO News for Oasmia Pharmaceutical
more
IPO Data
IPO File Date 07/06/2015
Offer Price $4.06
Price Range $4.70 - $6.70
Offer Shares (mm) 2.3
Deal Size ($mm) $9
IPO Data
IPO Date 10/22/2015
Offer Price $4.06
Price Range $4.70 - $6.70
Offer Shares (mm) 2.3
Deal Size ($mm) $9
Underwriters
more
Company Data
Headquarters Uppsala, Sweden
Founded 1999
Employees 80
Website www.oasmia.com